Orthopediatrics CORP

OrthoPediatrics Corp. presented its investor update for August 2026, detailing consistent year-over-year growth, a strong product innovation pipeline, and strategic expansion initiatives in the pediatric orthopedic market.

OrthoPediatrics Corp. stockholders approved the election of directors, executive compensation, and an increase in shares for the 2024 Incentive Award Plan.

OrthoPediatrics reports Q1 2026 revenue of $59.4 million, a 13% increase year-over-year, while reaffirming full-year 2026 guidance.

OrthoPediatrics reported 13% year-over-year revenue growth to $59.4 million and raised its full-year 2026 revenue guidance.

OrthoPediatrics Corp. amended its credit agreement, replacing a $50 million facility with a new $20 million delayed draw term loan, effectively reducing its total committed financing capacity.

OrthoPediatrics Corp. outlines strategic growth initiatives, product pipeline, and financial performance, projecting 2026 revenue of $262M-$266M and breakeven free cash flow.

OrthoPediatrics reports 13% revenue growth to $59.4 million for Q1 2026, driven by strong performance in trauma, deformity, and scoliosis product lines.

OrthoPediatrics Corp. reported a widened net loss in Q3 2025 despite revenue growth, driven by increased operating expenses, impairment charges, and restructuring costs.

OrthoPediatrics Corp. reported a 16% increase in net revenue for Q2 2025, reaching $61.1 million, but also saw its net loss widen to $7.1 million due to higher costs and restructuring expenses.

OrthoPediatrics Corp. announces a 17% increase in net revenue for the first quarter of 2025, driven by growth in trauma and deformity, scoliosis, and O&P bracing segments.

OrthoPediatrics Corp. saw a 37% increase in net revenue in the third quarter of 2024, driven by acquisitions and strong performance across its product lines.

OrthoPediatrics Corp. saw a significant increase in revenue during the second quarter of 2024, driven by acquisitions and strong performance across its product lines.

OrthoPediatrics Corp. announced a 15% revenue increase to $236.3 million in 2025, driven by core product performance and strategic acquisitions, despite continued operating losses.

OrthoPediatrics Corp. announces its financial results for the fiscal year ended December 31, 2024, showcasing revenue growth, strategic acquisitions, and a commitment to pediatric orthopedic care.

OrthoPediatrics Corp.'s 10-K filing provides a detailed overview of its capital stock, including common and preferred shares, as well as information on stock options, warrants, dividends, registration rights, and anti-takeover provisions.

David R. Pelizzon, a Director at Orthopediatrics Corp., has acquired 11,436 shares of common stock.

Bryan W. Hughes, a Director at Orthopediatrics Corp., acquired 11,436 shares of common stock on June 9, 2026.

Orthopediatrics Corp Director Kelly Laine Fischer acquired 11,436 shares of common stock on June 9, 2026, as reported in a Form 4 filing.

Samuel D. Riccitelli, a Director at Orthopediatrics Corp., acquired 11,436 shares of common stock on June 9, 2026.

Orthopediatrics Corp. Director Harold Ruf reported a transaction involving common stock on June 9, 2026.

David R. Bailey, President and CEO of Orthopediatrics Corp., acquired 119,140 shares of common stock on June 9, 2026.

OrthoPediatrics Corp. has scheduled its 2026 annual meeting of stockholders for June 4, 2026, to address director elections, executive compensation, and an incentive plan amendment.

OrthoPediatrics Corp. files an amendment to its proxy statement solely to include required Inline XBRL tagging in the Pay Versus Performance section, with no other changes to the document.

Orthopediatrics Corp. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

OrthoPediatrics Corp. will hold its 2025 annual meeting of stockholders on May 23, 2025, to elect directors, approve executive compensation, and ratify the appointment of Deloitte & Touche LLP as its independent auditor.

Orthopediatrics Corp. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

OrthoPediatrics Corp. will hold its 2024 annual meeting of stockholders on May 24, 2024, to elect directors, approve executive compensation, adopt an incentive award plan, and ratify the appointment of its independent auditor.

Several entities associated with Millennium Management have updated their beneficial ownership filings for OrthoPediatrics Corp., reporting a combined 3.2% stake.

Brown Capital Management, LLC reported a beneficial ownership of 4.31% in OrthoPediatrics Corp.'s Class A common stock as of September 30, 2025.

Millennium Management LLC and affiliated entities have reported a 5.5% passive beneficial ownership stake in OrthoPediatrics Corp. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.96% beneficial ownership stake in ORTHOPEDIATRICS CORP as of June 30, 2025, held for investment purposes.

Brown Capital Management, LLC has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in OrthoPediatrics Corp.'s Class A common stock as of March 31, 2025.

Brown Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 7.77% of OrthoPediatrics Corp.'s Class A common stock as of December 31, 2024.